TY - JOUR

T1 - Effects of the glucagon-like peptide-1receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease

T2 - A randomized, double-blind, placebo-controlled, crossover study

AU - Kumarathurai, Preman

AU - Anholm, Christian

AU - Fabricius-Bjerre, Andreas

AU - Nielsen, Olav W.

AU - Kristiansen, Ole

AU - Madsbad, Sten

AU - Haugaard, Steen B.

AU - Sajadieh, Ahmad

PY - 2017/5

Y1 - 2017/5

N2 - Objective: The glucagon-like peptide-1 receptor agonist liraglutide has been shown to reduce blood pressure (BP) in clinical trials using office BP measurements. However, the effects of liraglutide on 24-h BP and on the diurnal variation in BP have not been explored sufficiently. Methods: Forty-one patients with type 2 diabetes and stable coronary artery disease were randomized to receive liraglutide or placebo to a backbone therapy of metformin in this double-blind, placebo-controlled 12 along with 12 weeks crossover study. Ambulatory blood pressure monitoring (ABPM) was performed at the start and end of each intervention. Results: Twenty-four individuals completed all 24-h BP measurements. Liraglutide, when compared with placebo, did not induce any significant changes in mean 24-h SBP [difference R1.8mmHg (95% confidence interval, 95% CI:-4.33 to 7.93)] or DBP [+4.2mmHg (-0.74 to 9.17)]. Twenty-four-hour BP profiles revealed a trend for increase in evening SBP and DBP [+9.2mmHg (95% CI: 1.1-17.2) and R9.7mmHg (95% CI: 3.9-15.5), respectively]. Mean heart rate significantly increased after liraglutide [R7.6 bpm (95% CI: 2.56-12.62)]. Liraglutide did not affect the BP variability or the nocturnal BP dipping. Conclusions: We could not demonstrate any BP-lowering effect of liraglutide when using 24-h ABPM. Liraglutide exhibited diurnal variation in the effect on BP without affecting the BP variability or nocturnal BP dipping.

AB - Objective: The glucagon-like peptide-1 receptor agonist liraglutide has been shown to reduce blood pressure (BP) in clinical trials using office BP measurements. However, the effects of liraglutide on 24-h BP and on the diurnal variation in BP have not been explored sufficiently. Methods: Forty-one patients with type 2 diabetes and stable coronary artery disease were randomized to receive liraglutide or placebo to a backbone therapy of metformin in this double-blind, placebo-controlled 12 along with 12 weeks crossover study. Ambulatory blood pressure monitoring (ABPM) was performed at the start and end of each intervention. Results: Twenty-four individuals completed all 24-h BP measurements. Liraglutide, when compared with placebo, did not induce any significant changes in mean 24-h SBP [difference R1.8mmHg (95% confidence interval, 95% CI:-4.33 to 7.93)] or DBP [+4.2mmHg (-0.74 to 9.17)]. Twenty-four-hour BP profiles revealed a trend for increase in evening SBP and DBP [+9.2mmHg (95% CI: 1.1-17.2) and R9.7mmHg (95% CI: 3.9-15.5), respectively]. Mean heart rate significantly increased after liraglutide [R7.6 bpm (95% CI: 2.56-12.62)]. Liraglutide did not affect the BP variability or the nocturnal BP dipping. Conclusions: We could not demonstrate any BP-lowering effect of liraglutide when using 24-h ABPM. Liraglutide exhibited diurnal variation in the effect on BP without affecting the BP variability or nocturnal BP dipping.

KW - Ambulatory blood pressure monitoring

KW - Glucagon-like peptide-1

KW - Type 2 diabetes

U2 - 10.1097/HJH.0000000000001275

DO - 10.1097/HJH.0000000000001275

M3 - Journal article

C2 - 28129251

AN - SCOPUS:85010871771

VL - 35

SP - 1070

EP - 1078

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 5

ER -